Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Fortis Healthcare Limited — Q2 FY26
Fortis Healthcare delivered a strong Q2 FY26 with consolidated revenue of INR 2,331 crore (+17.3% YoY) and EBITDA margin expansion of 200 bps to 23.9%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q2 FY26 with consolidated revenue of INR 2,331 crore (+17.3% YoY) and EBITDA margin expansion of 200 bps to 23.9%. Hospital revenue grew 19.3% to INR 1,974 crore, driven by 5.8% ARPOB growth and 13% occupied bed increase. Oncology grew 29% YoY, contributing 16.2% of hospital revenue. Diagnostics EBITDA margin improved to 26.1% (vs 21.5% YoY). Management guided for sustained H2 momentum with 5-6% ARPOB growth and potential margin upside. Key risks include CGHS payment uncertainty and integration of Gleneagles O&M assets.
फोर्टिस हेल्थकेयर ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल आय 2,331 करोड़ रुपये रही, जो पिछले साल से 17.3% ज्यादा है। कमाई पर खर्च घटाने के बाद बचत (EBITDA मार्जिन) 23.9% हो गई, जो पहले से 2% बेहतर है। अस्पतालों की आय 19.3% बढ़कर 1,974 करोड़ रुपये हुई। इसकी वजह है कि हर मरीज से ज्यादा कमाई (5.8% बढ़ी) और भरे हुए बिस्तरों की संख्या (13% बढ़ी)। कैंसर के इलाज से आय 29% बढ़ी, जो अस्पताल की कुल आय का 16.2% है। डायग्नोस्टिक्स में बचत दर 26.1% हो गई (पिछले साल 21.5% थी)। कंपनी को उम्मीद है कि आगे भी अच्छा प्रदर्शन रहेगा, हालांकि सरकारी भुगतान और ग्लेनीगल्स के अस्पतालों के विलय में कुछ जोखिम हैं।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
CGHS payment uncertainty and policy changes
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
71%
+2pp YoY
Occupancy improved from 69% in Q1 FY26 to 71% in Q2 FY26, driven by higher patient volumes.
ARPOB (Annual Revenue Per Occupied Bed)
INR 2.51 crore
+5.8% YoY
ARPOB growth driven by improved specialty mix and 66% increase in robotic surgeries.
Oncology Revenue Growth
29%
+29% YoY
Oncology segment grew 29% YoY, increasing revenue share to 16.2% from 15%.
Diagnostics EBITDA Margin
26.1%
+460bps YoY
Agilus Diagnostics EBITDA margin improved to 26.1% from 21.5% YoY, driven by operational leverage.
What Changed vs Last Quarter
NEW
Hospital EBITDA margin to exceed initial guidance of 20.5-22.5%
Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.
NEW
Organic bed addition of 400-500 beds in FY26
Company added 550 operational beds in H1 FY26 and expects full-year addition of 400-500 beds.
NEW
ARPOB growth of 5-6% in H2 FY26
Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.
UPDATED
Diagnostics EBITDA margin of 23-24% for full year FY26
Agilus CFO guided margins to be around 23-24% for the full year, based on H1 performance of 24%.
DROPPED
Hospital EBITDA margin improvement of ~200 bps for FY26
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
DROPPED
Add ~900 beds in FY26, ~50% operationalized this year
Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
DROPPED
Diagnostics revenue growth to reach low double-digits in 6-8 quarters
Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.
NEW RISK
CGHS payment uncertainty and policy changes
Management expressed caution on CGHS due to non-predictability of payments and potential circular changes, despite recent rate increases.
NEW RISK
Integration risk from Gleneagles O&M agreement
The O&M arrangement for five hospitals may face operational challenges; future conversion to ownership is uncertain.
NEW RISK
Debt increase from acquisitions
Net debt rose to INR 2,219 crore (0.96x EBITDA) from 0.16x a year ago due to acquisitions, though management is comfortable.
NEW RISK
Delay in SMRI capacity addition
Commissioning of 225 beds at SMRI delayed by three months to March 2026, pushing revenue contribution to next fiscal.
RISK GONE
Gleneagles O&M assets may underperform expectations
Analyst raised concern that Gleneagles facilities have historically low margins (~3-4%), and the 3% fee may not capture full upside from operational improvements.
RISK GONE
Slow ramp-up of new brownfield beds could pressure margins
New bed additions (e.g., Manesar, FMRI) may take time to reach optimal occupancy, delaying margin contribution.
RISK GONE
Diagnostics revenue growth may remain below historical levels
Despite margin improvement, diagnostics revenue growth of 7.4% remains modest; management expects only gradual acceleration to double-digits.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q1 FY26, Q2 FY25, Q3 FY25
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
Mentioned in Q1 FY25, Q3 FY25
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Mentioned in Q2 FY25, Q4 FY25
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.
Mentioned in Q3 FY25, Q4 FY25
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
Mentioned in Q1 FY25, Q4 FY25
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
Fast read
Guidance and risk preview
Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.
Management expressed caution on CGHS due to non-predictability of payments and potential circular changes, despite recent rate increases.
View Risks →